|
First TR Treatment | HCM’s TV Moment
February 5, 2024
|
|
|
|
|
Together with
|
|
|
|
Surgeries & Interventions
|
|
|
|
|
|
Edwards Lifesciences ended last week with the biggest structural interventions launch that we’ve seen in some time, announcing the FDA approval of its EVOQUE transcatheter tricuspid valve replacement system (TTVR).
- The EVOQUE is the first TTVR therapy to receive FDA approval, following its European CE Mark in October.
- The TTVR system is indicated for patients with severe symptomatic tricuspid regurgitation (TR) who haven’t responded to optimal medical therapy.
The EVOQUE system features a nitinol self-expanding frame, intra-annular sealing skirt, and tissue leaflets made from the company’s bovine pericardial tissue. It will be available in three sizes, all delivered through the same low-profile transfemoral 28F system.
This design allows the EVOQUE system to replace the native tricuspid valve, “virtually eliminating tricuspid regurgitation in a wide range of patients,” and significantly improving patients’ symptoms and quality-of-life.
Those claims and the EVOQUE’s FDA approval are both supported by the recent TRISCEND II trial, which showed significant improvements after 6 months:
- 98% of EVOQUE patients improved from “severe, massive, or torrential” TR to “moderate or less,” versus just 21.6% of patients receiving optimal medical therapy.
- TTVR patients’ quality of life and functional status were also superior to medical therapy, including KCCQ scores (17.8 point avg. change), 6-minute walk tests (30.9m avg. difference), and NYHA symptoms (90% vs. 34.2% at NYHA I/II ).
- EVOQUE patients also had a lower major adverse event rate compared to Medicare patients who underwent isolated tricuspid valve replacement surgery (27.4% vs. 43.8%).
These results (and promising early data from 1-year follow-ups) suggest that EVOQUE could have a major impact on severe TR patients, who had no FDA-approved transcatheter options before now and faced challenges with surgical options.
However, other transcatheter TR therapies are available globally and could be headed stateside. Edwards also markets the Pascal and Cardioband TR valve repair systems in Europe (not yet FDA approved), and Abbott’s TriClip edge-to-edge TR repair system has a European CE Mark and has been submitted for FDA approval.
The Takeaway
Friday could prove to be a huge day for tricuspid regurgitation treatment in the US, given the EVOQUE system’s significant impact in TRISCEND II, and the limitations of current therapies. The fact that other TR approaches might also be on the way also suggests that we could be entering a new transcatheter era in TR treatment.
|
|
|
The Benefits of Outsourced Post-Processing
Using an outsourced cardiac image post-processing solution doesn’t have to mean sacrificing control of the results. Discover how PIA’s customizable post-processing workflow can help you get the most out of your images.
|
|
Explore the Potential of Cardio AI
Explore the potential of AI-powered cardiology solutions in this on-demand TeraRecon webinar, detailing how its Cardio Suite solutions help expedite disease diagnosis, care coordination, and provide the data to support cardiac treatment decisions.
|
|
Unify Your Cardiovascular Data
In this era of interoperability, it’s time to focus on cardiology. See how Change Healthcare’s enterprise cardiology platform provides a single database for CPACS, Hemo, CVIS, and ECGM — helping to improve data access and integrity while simplifying your IT configuration.
|
|
- CT First for Chest Pain: A study presented at the ACC Cardiovascular Summit provided solid support for cardiac CT’s guideline-recommended role as a first-line test for chest pain. The researchers analyzed 786 Atrium Health patients who had no prior diagnosis of coronary artery disease and underwent invasive coronary angiography to evaluate suspected angina. Patients who’s pre-ICA testing started with CCTA led to far more revascularizations (62%) than patients who received stress MRI, stress echo, no tests, or stress MPI (50%, 40%, 34%, 31%).
- Camzyos’ TV Moment: After months of online and radio ads focused on HCM awareness, Bristol Myers Squibb launched the first TV advertisement directly promoting its HCM drug Camzyos. The commercial focuses on how Camzyos helped alleviate the symptoms of a specific HCM patient, Mike, who can now enjoy more of what life has to offer. As Mike put it in the commercial, “this is my Camzyos moment.” Camzyos has historically been the only option for HCM, which remains widely underdiagnosed, although a new treatment from Cytokinetics appears to be on the way.
- Expanding MTEER Eligibility: Far more patients could potentially benefit from mitral valve transcatheter edge-to-edge repair (MTEER) than were included in the pivotal COAPT study of Abbott’s MitraClip. In an analysis of 6,675 MR patients who had MTEER, health status at 30 days was similarly improved among the sicker patients who wouldn’t have been eligible for COAPT and the eligible patients (77% vs. 78.9%). However, COAPT-ineligible patients’ one-year death rate was about twice as high (35.2% vs. 18.3%), leaving questions about the risks and benefits of expanding MTEER.
- Element Science’s Patch-Based WCD: Element Science took a step toward overcoming the patient comfort challenges that have hindered garment-based cardioverter defibrillator adherence, announcing the EU/UK approval of its Jewel Patch-Wearable Cardioverter Defibrillator. The Jewel P-WCD is far less bulky than current garment-based options and has shown in recent studies to effectively treat sudden cardiac arrest and improve patients’ wear-time compliance.
- AccurKardia’s New CPO: ECG analytics company AccurKardia made a big addition to its leadership team, naming Moin Hussaini as Chief Product Officer. Hussaini comes to AccurKardia following leadership roles at Edwards Lifesciences, GE HealthCare, Vyaire Medical, and Canon Medical Systems. Among other things, Moin will focus on developing AccurKardia’s non-arrhythmia based diagnostic portfolio. AccurKardia believes that ECG data can be used as a broader biomarker than its current use cases, and this can hold the key to effective telemedicine and remote patient monitoring globally.
- Dapagliflozin Stands Out in AFib Prevention: The SGLT2i dapagliflozin (AstraZeneca’s Farxiga) outperformed the SGLT2i empagliflozin (Boehringer Ingelheim/Lilly’s Jardiance) in a large real-world study of patients with type 2 diabetes. In about 138k matched South Korean patients, the rate of incidental AFib was lower for dapagliflozin in intent-to-treat (-11.5%) and sensitivity analyses (-16.5%), with consistent results across low and high CV risk groups.
- GE’s New EP Recorder: GE HealthCare announced the launch of its next-gen Prucka 3 with CardioLab EP Recording system, highlighted by signal-filtering and software enhancements that help electrophysiology labs maintain high signal fidelity while reducing environmental noise. The new Prucka 3 digital amplifier continues GE’s recent EP solutions portfolio update, following the launch of its CardioVisio for Atrial Fibrillation solution.
- FFR-Guided PCI Cost-Effective: In a prespecified analysis of the FRAME-AMI study (n=562), fractional flow reserve (FFR) guidance was more cost-effective than angiography for non-infarct related artery PCI in patients with acute MI. Compared to angiography, FFR-guided PCI increased quality of life years by 0.06 and decreased total per patient cost by $1,208. FFR guideance’s incremental cost-effectiveness ratio was $19,484 and its incremental net monetary benefit was $3,378, effectively proving that FFR is more cost-effective.
- Genomics plc’s Combo CVD Risk Tool: Genomics plc’s HEART study introduced a new integrated risk tool (IRT) that achieved high patient and provider satisfaction, and changed clinical decision making in 27.8% of cases where IRT scores surpassed the standard QRISK2 scores. The new tool combines polygenic risk data with QRISK2 scores, providing clinicians with a more individualized CVD risk assessment.
- Health Worker Exodus: COVID-19 had an obvious impact on the US healthcare workforce, and a new study revealed just how many of the US’ 18.8M healthcare workers left the profession during the pandemic. In JAMA Health Forum, researchers analyzed healthcare worker exit rates from 2018 to December 2021, finding that the Q1 2020 exit rate was well above 2018’s quarterly mean (8% vs. 5.9%), and the Q4 2021 exit rate was still far higher than the baseline 2018 period (7.7%).
|
|
A CCTA-Based Approach to Heart Attack Prevention
Cardiologists are increasingly relying on cardiac CT angiograms as a heart disease diagnostic tool. See what’s driving this trend in this Cleerly report detailing the key attributes of CCTA exams, evidence of its effectiveness, and CCTA’s medical guideline support.
|
|
Leveraging a Proven Echo AI Platform
Us2.ai has developed a promising new pathway for bringing custom echo AI applications into widespread clinical and commercial use – historically a challenge for algorithms produced by health systems and academic institutions. Find out how it worked in a Ugandan RHD program here.
|
|
- Bunkerhill Health’s Forbes Honors: Congratulations to Bunkerhill Health cofounders, David Eng and Nishith Khandwala, who were named to Forbes 30 under 30. Check out how they earned these honors in this Forbes profile.
- Monebo’s AF ECG Algorithm: Atrial fibrillation is often difficult to characterize with an automated algorithm due to the changing waveform morphology, system, or muscle noise. This is especially true given the size constraints of ambulatory devices to detect AFib. See how Monebo’s Kinetic AF ECG Algorithm overcomes these size limitations without sacrificing accuracy.
- Experience the future of learning: Medtronic Academy 2.0 is here! Unlock your ultimate destination for structural heart medical education with the newly redesigned Medtronic Academy 2.0. Gain access to expert-led courses, webinars, and a wealth of resources to stay ahead in cardiovascular care. Visit now!
|
|
|
|
|
